Trials / Sponsors / Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Academic / Other · 15 registered clinical trials — 13 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hema Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Phase 1 / Phase 2 | 2026-10-01 |
| Recruiting | An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma Neuroblastoma | Phase 1 / Phase 2 | 2025-11-05 |
| Recruiting | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | 2025-10-01 |
| Recruiting | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients W Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | 2025-10-01 |
| Not Yet Recruiting | The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR Leukemia, Lymphoma | Phase 1 / Phase 2 | 2025-09-01 |
| Recruiting | Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma Neuroblastoma | Phase 1 | 2025-01-28 |
| Recruiting | CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patie Acute Myeloid Leukemia in Children | Phase 2 | 2024-02-06 |
| Recruiting | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | 2023-11-14 |
| Withdrawn | HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematol Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | 2023-10-01 |
| Recruiting | CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients Acute Myeloid Leukemia in Children | Phase 3 | 2023-07-14 |
| Recruiting | International Leukemia Target Board Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy | — | 2022-12-31 |
| Recruiting | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Le Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia | Phase 3 | 2022-12-15 |
| Recruiting | Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor | Phase 1 / Phase 2 | 2022-08-18 |
| Recruiting | Vyxeos® With Clofarabine for Pediatric AML Relapsed Pediatric AML, Refractory Pediatric AML | Phase 1 | 2020-11-06 |
| Unknown | Central Line-associated Bloodstream Infection Prevention Using TauroLock-Hep100 in Pediatric Oncology Patients Central Line-associated Bloodstream Infection (CLABSI) | N/A | 2020-10-27 |